These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 29576265)

  • 1. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
    Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
    JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Hu X; Hay JW
    Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
    Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
    BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.
    Wymer KM; Sharma V; Saigal CS; Chamie K; Litwin MS; Packiam VT; Mossanen M; Pagliaro LC; Borah BJ; Boorjian SA
    J Urol; 2021 May; 205(5):1326-1335. PubMed ID: 33347775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
    Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
    Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.